As a great protein machine, ubiquitin-proteasome has become an important target for scientists to develop potentially effective drugs for diseases in recent decades of research.
US-based biopharmaceutical firm BridgeBio Pharma has raised $299.2m in a new financing round led by its existing investors KKR and Viking Global Investors.....
UK health technology firm BenevolentAI and the Association of Medical Research Charities are continuing an award encouraging use of artificial intelligence (AI) to develop new therapies for a second year.
Daphne Koller has unveiled her next goal: improving drug R&D. The ex-Calico AI expert plans to enlist data and machines to address shortcomings in drug discovery and development...